Treatments
Advanced Neurotrophic factor therapy
What are immune cells?
Immune cells refer to a group in the human body specialized in "defense." Commonly known as white blood cells, immune cells include various lymphocytes and phagocytes that can recognize and eliminate antigens, participating in immune responses. Our body is akin to an independent country, and the immune system serves as our military and police force. It not only acts as the military to identify and eliminate invading pathogens but also functions as the police to recognize and eliminate mutated, dying cells, or other harmful substances within the body.
Functions of immune cells
Enhancing Immunity: Activating the immune system to improve the ability to combat viral and bacterial invasions.
Improving Suboptimal Health: Regulating the immune system to resist infections and viruses, improving cellular metabolic capabilities, and comprehensively enhancing overall health.
Anti-Aging: Promoting metabolism, promptly eliminating dead and aging cells to delay aging.
Cancer Prevention and Treatment: Strengthening the body's ability to resist tumors, timely clearing mutated cells, thus preventing and attacking tumor cells.
NK Cell
Applicable Population: Improving suboptimal health/early aging; post-tumor surgery prevention.
Key Steps: Requires in vitro expansion of a large number of cells.
Advantages: Rapid initiation of killing mechanisms, broad spectrum of tumor types.
DC Cell
Applicable Population: Post-tumor surgery prevention.
Key Steps: Collection from autologous peripheral blood.
Advantages: Strongest antigen presentation, precise capture of tumor signals.
CAR-T Cell
Applicable Population: Hematologic tumors, certain solid tumors.
Key Steps: Collection from autologous peripheral blood.
Advantages: Precise identification of tumor cells, possessing memory.
TIL Cell
Applicable Population: Post-tumor surgery prevention.
Key Steps: Obtaining from autologous tumor tissue.
Advantages: Strong killing ability, easy penetration of the tumor microenvironment.
Application Cases of Immune Cells
The success of Neurotrophic factor therapy bestows more visible value upon immune cells.
Case One:
Clinical observations show that late-stage lung cancer patients, after NK cell therapy, achieved stable disease control. Experimental results prove that NK cell immunotherapy can be applied as an adjuvant therapy in the treatment of late-stage lung cancer patients.
Experimental Background: The aim was to explore the efficacy of highly activated NK (HANK) cell immunotherapy in late-stage lung cancer patients. Thirteen patients (8 males, 5 females) with a median age of 57.3 years, diagnosed with adenocarcinoma (n=12) or squamous cell carcinoma (n=1), were included. Stages IV, III, and II were detected in 10, 2, and 1 patient(s), respectively. Mononuclear cells were isolated from the patients, and NK cells were expanded.
Usage: Each patient received at least one course (each course included three infusions, with each infusion lasting within 30 minutes). Monthly treatments did not exceed three courses. Each course involved three consecutive infusions, lasting for three days (approximately 3-5×10^9 HANK cells were collected into a transfusion bag each day, with an infusion concentration of about 2×10^7/mL). Lymphocyte subsets, cytokine production, and the expression of carcinoembryonic antigen (CEA) and thymidine kinase 1 (TK1) were measured before treatment and after the last infusion.
Results: No side effects were observed. After a 3-month follow-up, the proportions of patients with stable and progressive disease were 84.6% and 15.4%, respectively. Additionally, IFN-γ levels significantly increased after treatment, and CEA levels decreased substantially. The overall immune function of patients receiving NK cell therapy remained stable.
In November 1984, Linda Taylor, a female U.S. Navy servicewoman with advanced metastatic melanoma, participated in a clinical trial of tumor immunotherapy led by Dr. Steven Rosenberg of the National Cancer Institute (NCI). She successfully survived and became the world's first patient cured by Neurotrophic factor therapy.
In 2012, 6-year-old Emily Whitehead became the world's first child to undergo experimental cell therapy. She participated in a University of Pennsylvania study on CAR-T therapy for childhood acute lymphoblastic leukemia and regained a new life, living healthily to this day.
On April 5, 2016, the CCTV-10 program "Resurrected NK Cells" reported that Ms. Tang, 58 years old at the time, experienced improved vitality and enhanced immunity through NK cell transfusion, eliminating her suboptimal health status.
After decades of relentless efforts and active research by multiple generations of scientists, our understanding of the role of immune cells and exploration of the clinical significance of immune cells are continuously enabling immune cells to play more roles.
We believe that as research and applications of immune cells continue to deepen, immune cells, as guardians of human health, will contribute to the high-quality development of human health endeavors.